Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-FU-induced gastrointestinal toxicity mechanisms in human colon
NL-OMON55582Active, not recruiting
- Sponsor
- Maastricht University
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of capecitabine in breast cancer and colorectal cancer (CRC) (3 cohorts), sponsored by Maastricht University. Primary endpoint: Whole genome transcriptomic response in colon epithelium. Started Jun 2019; status: active, not recruiting.
02
Drugs
capecitabine
03
Conditions
breast cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON55582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55582.